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The yeast Set2 histone methyltransferase is a critical enzyme
that plays a number of key roles in gene transcription and DNA
repair. Recently, the human homologue, SETD2, was found to be
recurrently mutated in a significant percentage of renal cell carci-
nomas, raising the possibility that the activity of SETD2 is tumor-
suppressive. Using budding yeast and human cell line model
systems,weexamined the functional significanceof twoevolution-
arily conserved residues in SETD2 that are recurrently mutated in
human cancers. Whereas one of these mutations (R2510H),
located in the Set2 Rpb1 interaction domain, did not result in an
observabledefect inSETD2enzymatic function,asecondmutation
in the catalytic domain of this enzyme (R1625C) resulted in a com-
plete loss of histone H3 Lys-36 trimethylation (H3K36me3). This
mutant showed unchanged thermal stability as comparedwith the
wild type protein but diminished binding to the histone H3 tail.
Surprisingly, mutation of the conserved residue in Set2 (R195C)
similarly resulted in a complete loss of H3K36me3 but did not
affect dimethylated histone H3 Lys-36 (H3K36me2) or functions
associatedwithH3K36me2inyeast.Collectively, thesedata implya
critical role for Arg-1625 in maintaining the protein interaction
withH3 and specific H3K36me3 function of this enzyme, which is
conserved from yeast to humans. They also may provide a refined
biochemical explanation forhowH3K36me3 loss leads to genomic
instability and cancer.
Cancer is increasingly characterized by alterations in chro-
matin-modifying enzymes (1). SETD2, a non-redundant his-
tone H3 lysine 36 (H3K36)4 methyltransferase (2), has been
found to be mutated in a growing list of tumor types, most
notably in clear cell renal cell carcinoma (ccRCC) (1, 3, 4), but
also in high grade gliomas (5), breast cancer (6), bladder cancer
(7), and acute lymphoblastic leukemia (8–10). Recent studies
exploring intratumor heterogeneity in ccRCC identified dis-
tinct mutations in SETD2 from spatially distinct subsections of
an individual tumor, suggesting that mutation of SETD2 is a
critical and selected event in ccRCC cancer progression (11).
Mutations in SETD2 are predominantly inactivating, such as
early nonsense or frameshift mutations, which lead to non-
functional protein and global loss of H3K36 trimethylation
(H3K36me3) (4, 11, 12). Missense mutations tend to cluster in
two domains (1, 4, 12, 13): the SET domain, which catalyzes
H3K36me3 (14), and the Set2 Rpb1 interaction (SRI) domain,
which mediates the interaction between SETD2 and the
hyperphosphorylated form of RNA polymerase II (RNAPII)
(13).
SETD2 and its yeast counterpart, Set2, both associate with
RNAPII in a co-transcriptional manner (13, 15, 16). In yeast,
Set2 mediates all H3K36 methylation states (H3K36me1/me2/
me3) (17) and regulates the recruitment of chromatin-remod-
eling enzymes (Isw1b) and a histone deacetylase (Rpd3) (18)
that functions to keep gene bodies deacetylated, thereby main-
taining a more compact chromatin structure (19, 20) that is
more resistant to inappropriate and bidirectional transcription
(18, 21). The Set2/SETD2 pathway is also important for DNA
repair (22–27) in both yeast and humans, as well as for proper
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mRNA splicing (12, 28, 29). Although yeast Set2 canmediate all
forms ofH3K36methylation, SETD2only trimethylatesH3K36
(13). Othermethyltransferases (e.g.NSD2 andASH1L)mediate
mono- and dimethylation (14), indicating an increased com-
plexity of H3K36 regulation in higher eukaryotes. Consistent
with a more diverse role, H3K36me3 recruits a variety of effec-
tor proteins in addition to those that are recruited in yeast,
including DNMT3b, which regulates gene body methylation
(30); LEDGF, which functions in DNA repair (31); and
ZMYND11, which regulates co-transcriptional splicing and
transcription elongation (32, 33).
The structural and functional similarities between SETD2
and Set2 provide an exceptional opportunity in which existing
assays in Saccharomyces cerevisiae can be applied to investigate
the functional consequences of SETD2 mutations reported in
human cancer. In this work, we characterized cancer-associ-
ated SETD2 mutations that occur at evolutionarily conserved
residues in functionally important domains (i.e. the SET and
SRI domains). We discovered that a missense mutation in the
SET domain of SETD2 (R1625C) altered the capacity of this
mutant to engageH3, leading to reduced protein stability, and a
complete loss of H3K36me3. Strikingly, the same mutation in
yeast Set2 (R195C) resulted in an identical effect onH3K36me3
but not H3K36me1 or H3K36me2 levels (or biological out-
comes associated with these lower methylation states). Further
biological studies in human cells revealed that loss of
H3K36me3 in the R1625Cmutant leads to DNA repair defects,
thereby revealing a greater understanding of how this recurrent
mutation probably leads to a loss of SETD2 tumor-suppressive
activity.
Results
SETD2 and Set2 Share a High Degree of Structural and
Sequence Homology at Their SET and SRI Domains—SETD2
and Set2 share significant structural and functional homology.
SETD2 demonstrates strong sequence conservation at all of the
annotated functional domains present in yeast Set2: AWS
(associated with SET), 42%; SET (Su(var)3–9, Enhancer-of-
zeste, Trithorax), 56%; PS (post-SET), 59%; coiled-coil, 33%;
WW, 26%; and SRI (Set2 Rpb1-interacting), 35% (Fig. 1A).
Given this similarity, we compared the structure of the SETD2
and Set2 SET domains to identify highly conserved residues for
further study. The structure of the SET domain in SETD2 has
been solved by crystallography (34), whereas the SETdomain of
Set2 was predicted here using I-TASSER (35–38). When the
predicted structure of the Set2 SET domain was aligned with
the crystal structure of the SETD2 SET domain, the structures
were strikingly similar (Fig. 1B).We then examined the conser-
vation of amino acids previously reported to be mutated in
human ccRCC (1, 4, 11, 12) across six organisms (Homo sapi-
ens, Drosophila melanogaster, S. cerevisiae, Mus musculus,
Xenopus tropicalis, and Danio rerio). Seven of the nine ccRCC
mutations occur at residues that are conserved across all model
organisms (Fig. 1C). Additionally, three of these seven muta-
tions occur in a region previously identified to act as the cata-
lytic site for lysine methylation (13). One of these mutations,
R1625C, is found in a location that is adjacent to the S-adeno-
syl-L-methionine (SAM) binding site in the structure and thus
would be predicted to impact catalytic activity (Fig. 1B). This
residue is themost common site ofmissensemutation reported
in both CBioPortal (39, 40) and COSMIC (41). The specific
arginine to cysteine mutation is found in both glioma (5) and
ccRCC (1). Significantly, mutation of the corresponding resi-
due in S. cerevisiae is known to affect Set2 catalytic activity (42).
Given its location andmutation frequency, we chose thismuta-
tion for further analysis.
We then examined the sequence and structural conservation
of the SRI domain and the location of ccRCC-associated mis-
sense mutations. In contrast to the SET domain, primary
sequence of the SRI domain is less conserved across model
organisms (Fig. 1D). However, the aligned crystal structures of
yeast (43) and human (44) SRI domains display structural con-
servation (Fig. 1E). In particular, the predicted site of SETD2
andRNAPII interactionwas previously suggested to be the con-
cave surface between  helix 1 and  helix 2 (44). The physical
relationship of these helices appears conserved between Set2
and SETD2. We therefore selected the Arg-2510 residue for
further study because this amino acid is recurrently mutated
(R2510H and R2510L) in ccRCC (1, 12) and is predicted to be
important for SETD2-RNAPII interaction by in vitro peptide
interaction assays (44).
SET Domain Mutation Destabilizes SETD2 in Cells—To
establish a human cell system in which to study the function
of SETD2 mutants, we generated SETD2-deficient cells
(SETD2). TAL effector nucleases (TALENs) (45, 46) targeting
exon 3 of SETD2 were introduced into two immortalized kid-
ney cell lines (human SV40 immortalized proximal tubule kid-
ney cells (HKC) (47) and 293T). Individual clones of TALEN-
treated cells were isolated, and loss of H3K36me3 was
demonstrated by immunocytochemistry (Fig. 2A). We verified
inactivation of both alleles of SETD2 via Sanger sequencing.
Representative allelic sequencing is shown (Fig. 2B).
We then exogenously expressed a truncated wild-type
FLAG-tagged form of SETD2 (amino acids 1323–2564;
tSETD2), which includes all known functional domains. The
R1625C or R2510H mutants were generated in tSETD2. Rela-
tive to tSETD2 and R2510H, R1625C protein levels were
reduced (Fig. 2C). R1625C mutant mRNA levels were also less
abundant (Fig. 2D). We examined protein stability after treat-
ment with the protein synthesis inhibitor cycloheximide. The
R1625C protein demonstrated a significantly shorter half-life
compared with that of wild type (Fig. 2E). In contrast, the half-
life of the R2510Hmutant was unchanged (Fig. 2E). These data
suggest that the decreased protein level of the R1625C SET
domain mutant results from both decreased RNA and a short-
ened protein half-life.
Histone H3 Lysine 36 Trimethylation Is Linked to SETD2
Mutational Status—We interrogated H3K36 methylation sta-
tus in cells transiently transfected with either tSETD2 or the
mutants R1625C and R2510H. Using immunocytochemistry,
we found that transfection of tSETD2 resulted in global resto-
ration of H3K36me3 (Fig. 2F), demonstrating that the N termi-
nus is not required for catalytic activity of SETD2. Transfection
of the R1625C (SET domain) mutant construct failed to restore
H3K36me3. In contrast, expression of the R2510H SRI mutant
globally restored H3K36me3.
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We next examined the H3K36 methylation status by Western
blotting analysis. Consistent with findings from immunocyto-
chemistry, SETD2 cells show complete loss of H3K36me3.
Trimethylation was restored to wild-type levels by expres-
sion of either the tSETD2 or the SRI mutant. In contrast, the
SET domain mutant failed to trimethylate H3K36 (Fig. 2G).
Monomethylation (H3K36me1) and dimethylation (H3K36me2)
were unaffected by SETD2 loss or expression of SETD2 variants
(Fig. 2G). These results are in agreement with the findings that
SETD2 is the exclusive H3K36 trimethyltransferase in mamma-
lian cells.
We then asked whether expression of either tSETD2 or
R2510H restored H3K36me3 to levels similar to those of wild-
type cells at specific loci. H3K36me3 levels have been shown to
increase along the gene body with preference for exons (48).
Using ChIP-qPCR, we examined the H3K36me3 levels at mul-
tiple exons of two genes,CDK2 andMYC, which had previously
been described (49). As expected, SETD2 cells displayed low
H3K36me3 levels at all sites (Fig. 2H). Expression of tSETD2
recapitulated the previously described pattern for H3K36me3
in wild-type cells (49) at both CDK2 and MYC, with higher
signal at exons 5 and 6 relative to exon 1 in CDK2, and in exons
2 and 3 relative to exon 1 inMYC. Cells expressing the R1625C
SET domain mutant displayed loss of H3K36me3 at levels sim-
ilar to that of SETD2 cells. Finally, expression of the R2510H
mutant also showed greater signal at later exons, indicating that
this point mutation restores not only the levels of methylation
but also the spatial placement of thesemethylmarks on actively
transcribed genes.
The SETD2 R1625C Variant Is Enzymatically Inactive in
Vitro and Has Diminished Substrate Binding—Given that the
R1625C SETD2 variant is associated with loss of H3K36me3 in
cells, we asked whether the R1625C mutation disrupts the
methyltransferase activity of SETD2 in vitro. To do this, we
expressed and purified from bacteria a wild-type or R1625C
mutated fragment of SETD2 (residues 1345–1711) containing
the SET domain. Both the wild-type and the R1625C SET
domain constructs yielded soluble proteins that were 90%
FIGURE 1. SETD2 and yeast Set2 show high sequence and structural conservation. A, comparison of SETD2 and yeast Set2 (ySet2) annotated protein
structure. The percentage of conserved residues within the BLAST-aligned domain sequence is indicated. Annotated domains include AWS, SET, PS, CC, LCR,
WW, and SRI. Numbers represent percent conservation. B, alignment of human SET domain crystal structure (blue) with I-TASSER protein structure prediction
for yeast SET domain (yellow). The N terminus is marked in green, the C terminus is marked in pink, and residues mutated are shown as sticks. C, partial SET
domain sequence alignment across multiple species. Amino acids 1612–1673 of the human SET domain (amino acids 1550–1667) are shown. Residues
mutated in ccRCC are shown in red andmarkedwith an asterisk. The arrow indicates Arg-1625, the residuemutated for study. The black box indicates residues
previously shown to be an important catalytic site. Residues that are conserved across species are indicated in green.D, SRI domain sequence alignment across
multiple species. Residuesmutated in ccRCC are in red andmarkedwith an asterisk. The arrow indicates Arg-2510, the residuemutated for study. Residues that
are conserved across species are indicated in green. E, alignment of the human SRI domain crystal structure (blue) with the yeast SRI domain crystal structure
(yellow). The N terminus is marked in green, the C terminus is marked in pink, and residues mutated are shown as sticks.
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pure as assessed by SDS-PAGE (Fig. 3A). Methyltransferase
activity was then assessed using a radiometric assay with
chicken oligonucleosomes as the substrate. Whereas wild-type
SETD2 displayed robust activity, the R1625C variant displayed
little enzymatic activity over the no enzyme control (Fig. 3B).
We next sought to determine why the R1625C variant is cat-
alytically inactive. We first considered whether this mutation
results in a misfolded protein, thereby inactivating the SET
domain. We compared the CD spectra of the wild-type SETD2
with the R1625C variant. The CD spectra in the low UV range
(185–260 nm) of the wild type and the R1625C variant were
nearly indistinguishable, suggesting that the R1625C substitu-
tion does not alter the secondary structure of the SET domain
(Fig. 3C). To determine whether the R1625C variant alters the
thermal stability of the SET domain, we monitored the CD sig-
nal at the 207-nm peak over a temperature range from 20 to
95 °C. Both thewild type and the R1625C variant showed highly
similar thermal melt curves with amelting temperature (Tm) of
55 °C (Fig. 3D). Together, these results suggest that the loss of
catalytic activity observed for the R1625C variant is not due to
protein misfolding or reduced thermal stability.
Structural analysis of the SETD2 SET domain shows that
Arg-1625 is positioned within the active site, opposite the SAM
binding pocket, and is located about 7 Å away from the sulfur
group of S-adenosyl-L-homocysteine (SAH) (Fig. 3E). Although
substitution of Arg-1625 with cysteine would not be expected
to directly disrupt SAM binding, the Arg-1625 side chain
engages in three hydrogen bonds with the backbone carbonyl
oxygens of Ala-1617 and Thr-1618 (Fig. 3E). Substituting cys-
teine for Arg-1625 using in silico mutagenesis showed that
every possibly cysteine rotamer would cause steric clashes. The
cysteine side chain would not recapitulate the hydrogen bond-
ing network ofArg-1625when oriented in the samedirection as
the Arg-1625 side chain observed in the crystal structure (Fig.
3F). Although no structure of the SETD2 SET domain ternary
complex containing histoneH3 is available, the location of Arg-
1625 in close proximity to, but opposite, the SAM binding
pocket suggests thatArg-1625may directly or indirectly engage
H3 ormaymaintain local structural integrity that aids substrate
binding.
To determine whether the R1625C variant has altered sub-
strate binding, we performed peptide pull-down experiments
FIGURE 2. ccRCC-specific mutations in SETD2 have separate effects on H3K36me3. A, immunocytochemistry of HKC SETD2 wild-type (top) and SETD2
cells for H3K36me3. B, Sanger sequencing results of TALEN target sequence in exon 3 of SETD2. Two allelic variants in one HKC SETD2 clone are represented.
C, immunoblot displaying protein expression level 72 h after transfection in 293T cells. Ku80 acts as a loading control.D, average quantification of SETD2/Ku80
over 12 h following cycloheximide treatment in three independentWestern blots (left). Right, average half-life ofmutant SETD2 proteins. E, average RNA levels
of tSETD2, R1625C, or R2510H, as determined by qPCR for tSETD2 levels. F, anti-H3K36me3 immunocytochemistry on HKC at 72 h post-transfection following
reintroduction of GFP,wild-type tSETD2, R1625C, or R2510H.G, anti-H3K36methylation immunoblot displaying levels ofmethylation at 72 hpost-transfection
following reintroductionofGFP,wild-type tSETD2, R1625C, or R2510H.QuantificationofH3K36me3/H3 levels is shownbelow theblot.H, ChIP-qPCRdisplaying
H3K36me3 levels at exonic locations in CDK2 (left) and MYC (right), displayed as ChIP signal/input. Error bars, S.E. Significance comparisons were made with
SETD2-inactive GFP.
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using histone H3 peptides that were unmodified or were meth-
ylated at Lys-36. The pull-down experiments showed that the
R1625C variant associated with all of the histone peptides to a
lesser degree comparedwith thewild-type SETD2SETdomain,
suggesting that the R1625C substitution weakens substrate
binding (Fig. 3G). Taken together, our results suggest that the
R1625C substitution impairs enzymatic activity by reducing
substrate binding, which is probably a consequence of fine
structural disturbances induced by loss of the Arg-1625 hydro-
gen bonding network within the active site.
Domain-specific Mutations in Yeast Set2 Separate Roles of
H3K36 Methylation States—To further explore the functional
significance of ccRCC-associated mutations, we took advan-
tage of several well characterized phenotypic assays in S. cerevi-
siae. Using set2 cells, which are devoid of all H3K36 methyla-
tion (42), we created strains that either contained vector alone
or exogenously expressed either wild-type or mutated forms of
Set2. Mutant forms of Set2 included the homologous SETD2
SET domain mutant (R195C), the homologous SETD2 SRI
mutant (K663L), or a control SET domainmutant (H199L) pre-
viously characterized to disrupt both tri- and dimethylation
while retaining monomethylation activity (42). As expected,
Set2 loss resulted in the complete absence of mono-, di-, and
trimethylation of H3K36, which was rescued upon the addition
of wild-type SET2 (Fig. 4A). As shown previously, the H199L
mutant only restored monomethylation. In contrast, whereas
the K663L mutant restored all H3K36 methylation states, the
R195Conly restoredH3K36mono- and dimethylation. Intrigu-
ingly, the restoration of H3K36 mono- and dimethylation by
the R195C mutant mimics the status of SETD2-deficient
human cells (i.e. both have a selective loss of H3K36me3).
Because the SETD2 R1625C mutant demonstrated decreased
protein stability in human cells, we examined protein levels of
the R195C mutant in the yeast cells. Following cycloheximide
treatment, we observed decreased protein levels of the R195C
mutant relative to wild-type Set2, particularly at 3 h post-treat-
FIGURE 3. The SETD2 R1625C variant is catalytically inactive and has reduced substrate-binding capacity. A, Coomassie Blue-stained SDS-polyacryl-
amide gel of 1 g of purified wild type or R1625C variant SETD2 construct containing amino acids 1345–1711 (42 kDa). Precision Plus protein standards
(Bio-Rad) are annotated. B, radiometric histone methyltransferase assays comparing the catalytic activity of the wild type and R1625C variant when chicken
oligonucleosomes were the substrate. The amount of 3H-methyl incorporated is quantified as cpm, and error bars represent S.E. (n 3). A reaction without
enzyme served as a negative control. C, CD absorbance spectra (plotted as the molar ellipticity ([]) as a function of wavelength) comparing the secondary
structure of wild type SETD2 (black) and the R1625C variant (purple). D, thermal melt curves showing the change in CD absorbance at 207 nm over the
temperature range from 20 to 95 °C for wild type SETD2 (black) and the R1625C variant (purple). E, structural analysis of Arg-1625. The crystal structure of the
SETD2 SET domain (show in tan) bound to SAH (shown in green) near the active site. Hydrogen bonds are shown as gray dashed lines (Protein Data Bank code
4H12). F, in silicomutagenesis analysis (performed in PyMOL, Schro¨dinger Inc.)). The distances between the R1625C thiol and the carbonyl oxygens of Ala-1617
and Thr-1618weremeasured in PyMOL (yellow dashed lines).G, peptide pull-down assays comparing the binding of thewild type and the R1625C variant with
the indicated histone H3 peptides. All peptides were biotinylated at the C terminus and were unmodified or were modified as indicated. Streptavidin-coated
magnetic beads without peptide served as the negative control. Short (top) and Long (bottom) refer to exposure length.
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ment. This effect was rescued by treatment with the proteosome
inhibitor MG132 (Fig. 4B). This suggests that, as in humans, the
R195C variant is less stable than wild type in yeast cells.
Loss of Set2 has been implicated in various phenotypes in
S. cerevisiae, including transcription elongation defects, cryptic
initiation, and sensitivity to DNA-damaging agents (42). We
askedwhether theR195CSet2mutantwould be associatedwith
any of these phenotypes. To examine transcriptional elongation,
we performed a spotting assay in the presence of the transcription
elongation inhibitor 6-azauracil (6-AU). This assay has been used
previously to assay for the presence of transcriptional elongation
defects in yeast (16). As expected, wild-type yeastwere sensitive to
6-AU (200 g/ml), whereas set2 cells were resistant to this drug
(Fig. 4C) (16). Although expression of wild-type SET2 restored
sensitivity to 6-AU, the H199L mutant did not. The R195C and
K663Lmutants behaved similar towild-type Set2.These data sug-
gest that H3K36me2 is primarily responsible for the sensitivity to
inhibitors of transcriptional elongation.
Cryptic initiation has been previously associated with Set2
loss (18). We therefore assessed the effects of our Set2 muta-
tions in a cryptic transcription reporter assay. This assay mon-
itors the growth of yeast cells that contain theHIS3 gene with a
cryptic start site that exists in the FLO8 gene. Importantly, the
cryptic start site is out of frame when the 5 promoter is used,
and a functional transcript is only produced if the 3 cryptic
start site is utilized. In this setting, cryptic transcription results
in expression of HIS3, which can restore growth in medium
lacking histidine. Consistent with previous results (18), loss of
Set2 permits growth in the absence of histidine (Fig. 4D). No
growth was observed in the cells expressing the R195C or
K663Lmutants. However, cell growth occurred in the presence
of theH199Lmutant (Fig. 4D).Thesedata indicate that trimeth-
ylation is dispensable for preventing cryptic initiation, whereas
dimethylation is required to suppress this phenotype.
Recent studies have demonstrated that yeast lacking Set2
cannot properly activate the DNA damage checkpoint (42, 50).
To determine whether the RCC-associated SET domain muta-
tion impacts this phenotype, we assessed the impact of the Set2
point mutants on growth in the presence of phleomycin, a dou-
ble strand break-inducing agent. As expected, set2 cells dis-
FIGURE 4. Modeling of ccRCC specific mutations in Set2 results in separate effects based on H3K36 methylation status. A, anti-H3K36 methylation
immunoblots displaying levels of methylation in set2 yeast cells as well as yeast with the indicated Set2mutation. Quantification of H3K36me3/H3 is shown
as a bar graph. B, Western results for Set2 and R195C protein levels after treatment with cyclohexamide (100g/ml) andMG132 (75M). C, 6-AU treatment of
wild-type or set2 yeast cells expressing the indicated Set2mutations.D, phleomycin treatment of wild-type or set2 yeast cells expressing the indicated Set2
mutations. E, cryptic initiation assay of wild-type or set2 yeast cells expressing the indicated Set2 mutations. F, table summary of yeast phenotypes for each
of the Set2 mutants
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played increased sensitivity to phleomycin relative to Set2wild-
type yeast (Fig. 4E). set2 cells expressing either wild-type Set2
or the R195C or K663L mutants showed sensitivity similar to
that of the wild-type rescue. However, yeast expressing the
H199Lmutant showed a level of sensitivity similar to that of the
set2 cells (Fig. 4E). Taken together, these data indicate that
the cellular phenotypes associated with Set2 loss in yeast are
associated with H3K36me2 and that H3K36me3 is dispensable
for these activities (summarized in Fig. 4F).
Human Kidney Cells Display an H3K36 Trimethylation-
dependent DNA Damage Response—Because of the exclusivity
of SETD2 in mediating trimethlyation in human cells, we
studied phenotypes similar to those examined in yeast in
human cells that express ccRCC-relevant mutants. We first
examined the effect of the transcriptional elongation inhibitor
5,6-dichlorobenzimidazole 1--D-ribofuranoside (DRB) on cell
survival. DRB inhibits CDK9, which results in premature ter-
mination of transcription (51). Assessing viability at 12 h time
points for 3 days, we observed that DRB-associated toxicity did
not differ between SETD2 wild-type and SETD2 cells (Fig.
5A).
Several recent studies have examined the effect of SETD2
loss in human cells on the response to DNA damage (22–26).
To further explore the role of H3K36me3 in the DNA damage
response, we irradiated HKC to 2 Gy and then performed im-
munofluorescence for H2A.X, a marker of DNA damage. At
30 min postirradiation, H2A.X foci were seen in all cell types
at similar levels (Fig. 5B). In untransfected and in control trans-
fected wild-type cells, the number of foci greatly decreased by
1 h and largely resolved by 4 h. However, in SETD2 cells, the
number of H2A.X foci remained elevated at both 1 and 4 h.
Expression of tSETD2 in SETD2 cells led to resolution of foci
at time points similar towild-type cells. Cells expressing the SRI
mutant, R2510H, also showed rapid foci resolution. However,
foci persisted in cells expressing the R1625C mutant (Fig. 5B).
Quantification of these results demonstrated that both
SETD2 cells and R1625C-expressing cells had a significantly
higher percentage of cells with greater than 10 foci compared
with the other conditions (Fig. 5C).
We quantified H2A.X by immunoblotting, enabling us to
account for changes in total protein and histone levels. These
studieswere performed in 293T cells, as additional validation of
results in HKC. As observed with HKC, regardless of SETD2
status, 293T cells showed increased total H2A.X at 30 min
postirradiation (Fig. 5D). By 4 h, H2A.X levels returned to
baseline in cells with H3K36 trimethylation (WT, tSETD2, and
R2510H). However, elevated levels of H2A.Xwere observed in
cells lackingH3K36me3 associated with SETD2 loss or R1625C
expression. Finally, we examined the effect of irradiation on
viability using a colony formation assay. The fraction of surviv-
ing colonies did not differ between SETD2 wild-type and
SETD2 cells (Fig. 5E). Overall, these findings demonstrate
that SETD2-mediated H3K36me3 is coupled to the efficient
resolution of double strand breaks. Corresponding to results in
yeast, loss of trimethylation is not associated with enhanced
sensitivity due to inhibition of transcriptional elongation or
from DNA damage.
Discussion
In an effort to explore the function of missense mutations
identified in human cancers, we examined several recurrent
mutations that occur at evolutionarily conserved residues in
yeast and human cell lines. The striking homology between
SETD2 and Set2 creates an opportunity to compare the effects
of mutations while taking advantage of the strengths of each
model system. Indeed, a recent study (52) also modeled cancer
mutations in yeast, highlighting the utility and power of yeast to
be a robust model system to aid in human protein analyses. In
this paper, we investigated how two highly conserved SETD2
residues that are commonly mutated in cancer affect the func-
tions of this enzyme. Limited studies have explored the poten-
tial roles that SETD2 loss may play in cancer development. We
found that mutation of the SET domain, but not the SRI
domain, resulted in effects in the human and yeast assays. Spe-
cifically, we identified R1625C as a critical mutation that
impacted SETD2 enzymatic activity and protein stability in
cells, an effect also noted when this mutation was modeled in
yeast Set2. Loss of H3K36me3 in human cells also led to defects
in DNA repair, indicating a potential mechanism by which
SETD2 functions as a tumor suppressor. To our knowledge,
this study is the first to dissect the impact of cancer-associated
mutations in SETD2 and further validate using yeast as amodel
to complement human cell analyses.
A key discovery emerged from the study of the R1625C
mutant. In contrast to the human R1625C variant, which was
catalytically inactive in vitro, the homologous substitution in
yeast Set2 led to an uncoupling of di- and trimethylating activ-
ities. This suggests that this residue may be important for the
specific trimethylating activity of the enzyme. Moreover, many
substrate binding interactions govern stability. Thus, the
reduced protein stability (in the absence of other thermal insta-
bility) may reflect a structural role that differentiates mono-,
di-, and trimethylating activity. Because of this unique mode of
regulation, the R195C mutation allowed us to examine the
functions specifically associated with the trimethylated state of
H3K36 in cells (i.e. impaired transcriptional elongation, cryptic
initiation, and impaired survival in the face of DNA damage).
Consistent with other reports that examined cryptic initiation
(19, 53), we found that H3K36me3 is dispensable, whereas
H3K36me1/me2 is required to suppress cryptic initiation as
well as for transcription elongation and DNA damage survival
phenotypes. In contrast, the SET domain mutation in SETD2
had a similar impact onH3K36me3 levels but resulted in a clear
DNA damage response phenotype.
These studies offer a rationale for differences in observed
phenotypes in SETD2 deficient human cells associated with
Set2 loss in yeast, including cryptic initiation and impaired
transcriptional elongation. However, impaired response to
DNAdamage, aswe observed, has been reported for bothmam-
malian systems and Set2 in yeast, linking this feature with
H3K36 trimethylation. The H2A.X results suggest that reso-
lution of DNA strand breaks in human cells requires
H3K36me3. (Due to the presence of multiple H3K36 dimethy-
lating enzymes in mammalian cells, absence of H3K36me2 is
rarely encountered in human models.) H3K36me2 is induced
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by ionizing radiation and improves association of early DNA
repair components with an induced break and improved repair
by non-homologous end joining in human cells (27). Although
our data show that the resolution of strand breaks, as measured
by clearance of H2A.X foci, was delayed in the absence of
H3K36me3, our data also shows that H3K36me3 loss does not
affect viability after radiation in mammalian cells. Thus, loss of
dimethylation may convey a sensitivity to DNA damage that is
not present in the absence of SETD2 trimethylating activity. It
is important to consider thatmultiple factorsmay influence cell
death in transformed cells. However, these distinct findings in
yeast and mammalian systems indicate a complex level of reg-
ulation of DNA repair mediated by the histone code at H3
lysine 36. Multiple studies have concluded that the loss of
SETD2 confers a variety of types of genomic instability, ranging
from microsatellite instability to impairment of non-homo-
FIGURE 5.H3K36me3 loss delays H2A.X foci resolution after DNA damage but does not alter viability. A, surviving fraction of cells at 12, 24, 36, 48, and
72 h post-treatment with 100 M DRB. Fraction was determined compared with an untreated control. Error bars, S.D. of triplicate treatments. B, H2A.X foci
formation at 0, 0.5, 1, and 4 h after irradiation (2 Gy) in HKC wild-type or SETD2-inactivated cells transfected with GFP, tSETD2, R1625C mutant, or R2510H
mutant. The nuclei were visualized by DAPI staining. Representative immunofluorescence images are shown. Scale bar, 10 m. At least five fields were taken
from each condition, and four independent experiments were performed. C, percentage of HKCwith10 H2A.X foci/cell at 0, 0.5, 1, and 4 h after irradiation
(2 Gy). Error bars, S.E. *, p	 0.05; **, p	 0.01 (two-sided t test, comparison with HKC wild type). D, immunoblotting analysis for the expression of H2A.X and
H3 (loading control) from the 293 wild-type or SETD2-inactivated cells transfected with GFP, tSETD2, SET domain R1625C mutant, or SRI domain R2510H
mutant. The cells were irradiated by 2 Gy, and histones were acid-extracted at various time points. Shown is average quantification of H2A.X/H3 after
irradiation in three independent Western blots. Error bars, S.E. *, p	 0.05; **, p	 0.01; ***, p	 0.001 (two-sided t test, comparison with 293 wild type GFP).
E, radiation foci formation assay. The surviving fraction represents ratio of treatment (37, 75, 150, and 300 rads) to 0 rad comparison. Error bars, S.D. of triplicate
results.
SETD2/Set2 DomainMutations and H3K36Methylation
21290 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 291•NUMBER 40•SEPTEMBER 30, 2016
logous end joining (50, 54, 55). Our data agree with these
results.
Through modeling disease-relevant SETD2 mutations, we
were able to gain insight into H3K36me3 function and dissect
the roles of H3K36 dimethylation and trimethylation. Future
studies will further explore the roles of the SETD2 SRI domain
and examine the effects of additionalmutations andwill further
define the role of SETD2 loss in the development of kidney
cancer and other tumor types.
Experimental Procedures
Modeling SETD2 and Set2—The primary protein sequences
of Set2 from S. cerevisiae and SETD2 from H. sapiens were
compared via BLAST alignment analysis, and the percentage of
homology between annotated domains was determined using
the percentage overlap of the BLAST-aligned regions. The pri-
mary sequences of the SET and SRI domains of the enzyme
responsible for H3K36 methylation from H. sapiens, S. cerevi-
siae, X. tropicalis, D. melanogaster, D. rerio, and M. musculus
were aligned using ClustalOmega (56) and annotated with
reported SETD2 mutations in ccRCC (1, 4, 11, 12). The struc-
tures of the SETD2 SET domain (34), SETD2 SRI domain (44),
and Set2 SRI domain (43) have been reported previously. To
predict the structure of the yeast SET domain, the amino acid
sequence (UniProtKB, P46995) was submitted to I-TASSER
using the default parameters (35–38). The ribbon structures
were aligned using the align command in the PyMOLMolecu-
lar Graphics System (57).
Mammalian Cell Lines Transfections and Phenotypic
Assays—293T human embryonic kidney cells were generously
provided by Dr. Jenny Ting (University of North Carolina,
Chapel Hill, NC). The SV40 transformed human renal tubule
epithelial cell line (referred to as HKC) was obtained from Dr.
Lorraine Racusen (Johns Hopkins University, Baltimore, MD)
(47). A pair of vectors containing TALENs targeting exon 3 of
SETD2 was generated using the REAL (restriction enzyme
and ligation) assembly method. Component plasmids were
obtained from Addgene. Briefly, target sites were selected, and
TALENs were designed using Zifit, followed by assembly (46).
The TALEN target sequences are 5-TCATGTAACATCCAG-
GCC-3 and 5-ACAGCAGTAGCATCTCCA-3.
An expression construct containing anN-terminal truncated
form of SETD2 (amino acids 1323–2564; tSETD2) was
sequence-optimized for expression in human cells, tagged with
the FLAG sequence on the C terminus, and synthesized by Life
Technologies, Inc. tSETD2 was specifically used because it
models the yeast protein in domain structure, and expression of
full-length SETD2was technically unfeasible. tSETD2was sub-
cloned into the pINDUCER20 vector (58). Disease-relevant
SETD2 mutations were introduced into the tSETD2
pINDUCER20 construct using the QuikChange II site-directed
mutagenesis kit according to the manufacturer’s instructions
(Agilent Technologies).Mutations were verified through direct
DNA sequence analysis.
293T and HKC human renal cells were transfected with the
TALEN constructs, tSETD2 construct, and mutation con-
structs using the Amaxa cell line Nucleofector kit V (Lonza).
For the protein stability assay, cycloheximide (100 ng/ml) was
applied to cells 72 h post-transfection. For the DRB transcrip-
tion inhibition assay, 1000 cells/well were plated in triplicate on
a 96-well plate and treated with 100 M DRB for 72 h, with
viability beingmeasured every 12 h byCell TiterGlo (Promega).
Sequencing and Allelic Analysis—DNA was extracted, and
the SETD2 TALEN target site was PCR-amplified (primers
5-ACAGGGACGACAGAAGGTGTCATT-3 and 5-ACTG-
GTGCTGGTGATGAGAGTGTT-3), sequenced (Applied
Biosystems 3730xl Genetic Analyzers, Life Technologies) and
analyzed (Sequencher DNA analysis software version 5.0, Gene
Codes Corp.). Allelic analysis was performed by subcloning
individual PCR products (TOPO TA Cloning kit, 45-0641,
Life Technologies). DNA from individual clones was PCR-am-
plified, sequenced, and analyzed as described above.
Immunoblotting Analysis—To isolate mammalian cellular
proteins, cells were lysed in mammalian protein extraction re-
agent (Pierce) supplemented with Complete Mini Protease
Inhibitor Mixture (Roche Applied Science). Histones were
extracted using an overnight acid extraction protocol (Abcam).
For yeast immunoblots, asynchronously grown mid-log (0.6–
0.8 OD) phase cultures were lysed in SUMEB buffer using glass
beadmethods described on theGottschling laboratory website.
Antibodies—Antibodies used include SETD2 (HPA042451,
Sigma-Aldrich), Ku80 (ab3107, Abcam), H3K36me3 (ab9050,
Abcam), total H3 (Abcam, ab10799; Epicypher, 13-0001),
H3K36me2 (39255, Active Motif), H3K36me1 (ab9048,
Abcam), H2A.X (ab2893, Abcam), GST (EpiCypher, catalog
no. 13-0022), and Set2 (raised in the Strahl laboratory). Second-
ary antibodies used in human studies were anti-mouse and
anti-rabbit IRDye secondary antibodies from LI-COR Biosci-
ences (Lincoln, NE). HRP-conjugated donkey anti-rabbit sec-
ondary antibody was used (Amersham Biosciences) for yeast
studies. Human antibodies were detected using the Odyssey IR
imager (LI-COR Biosciences), and densitometry analysis was
performed using ImageStudio version 2.0. The yeast immuno-
blots were developed using ECL-Prime (Amersham Biosci-
ences), and densitometry analysis was done using ImageJ
(National Institutes of Health).
Immunocytochemistry—Cellswere fixedwith4%paraformal-
dehyde for 15min and permeabilized using 0.25%TritonX-100
in PBS. Endogenous peroxidase activity was blocked by incuba-
tion in 1% H2O2. Cells were then blocked in 5% bovine serum
albumin, followed by incubation in primary antibody. The Vec-
tastain ABC kit (PK6101, Vector Laboratories) was used for
secondary antibody andHRP conjugation, followed by theDAB
peroxidase substrate kit (SK-3100, Vector Laboratories) and
hematoxylin staining.
Chromatin Immunoprecipitation—Cells were fixed in 1%
formaldehyde for 10min, quenched with 125mM glycine treat-
ment, and homogenized in hypotonic solution (10mMTris, pH
7.4, 15 mM NaCl, 60 mM KCl, 1 mM EDTA, 0.1% Nonidet P-40,
5% sucrose, 1
 protease inhibitors). Nuclei were separated by
centrifugation through a sucrose pad (10 mM Tris, pH 7.4, 15
mMNaCl, 60mMKCl, 10% sucrose, 1
 protease inhibitors) and
then resuspended in ChIP buffer (10 mM Tris, pH 7.4, 100 mM
NaCl, 60mMKCl, 1mMEDTA, 0.1%Nonidet P-40, 1
protease
inhibitors, 0.05% SDS) and sonicated to obtain DNA between
200 bp and 1 kb. DNA was immunoprecipitated with
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H3K36me3 antibody prebound to protein A/G beads. Immu-
noprecipitated complexes were washed and RNase- and Pro-
teinase K-treated, and protein-DNA cross-links were reversed
by overnight incubation at 65 °C.
Quantitative RT-PCR—Total RNA was extracted using the
Qiagen RNeasyminikit. cDNAwasmade from total RNA using
random primers and Superscript II reverse transcriptase re-
agents (Invitrogen). Primers used for RT-PCR are listed in
Table 1.
Expression and Purification of Human SETD2—An E. coli
codon-optimized synthetic gene corresponding to human
SETD2 (UniProtKB ID Q9BYW2) residues 1345–1711 fol-
lowed by a stop codon was cloned into the pGEX-6P-2 expres-
sion vector (GE Healthcare) using standard procedures. The
protein was expressed in soluBL21 (DE3) (Amsbio) cells by
growing cells in Terrific Broth II medium (MP Biomedicals) at
37 °C until anA600 of0.6 and then chilling the cells for 30min
at 4 °C before inducing them with 1 mM isopropyl 1-thio--D-
galactopyranoside in the presence of 25 M ZnCl2 for 20 h at
16 °C. Cells were harvested by centrifugation, and pellets were
flash-frozen in liquid nitrogen. For purification, thawed cell
pellets were resuspended in binding buffer (50mMTris, pH 7.3,
300 mM NaCl, 4 mM DTT, 10% glycerol, and 1 M ZnCl2) sup-
plemented with 1 Complete mini-EDTA-free protease inhibi-
tor tablet (Roche Applied Science), 0.1 mM PMSF, 0.5 mg/ml
chicken egg lysozyme, and 0.2% (v/v) Triton X-100 and incu-
bated on ice for 45 min and then lysed with sonication and
clarified by centrifugation. Clarified lysates were diluted 1:2
with binding buffer and applied to a 5-ml glutathione-agarose
gravity flow column (pre-equilibrated with 10 column volumes
of binding buffer) at a flow rate of 0.5 ml/min at 4 °C. The
bound protein was washed with 10 column volumes of binding
buffer and then eluted from the column with 35 ml of elution
buffer (50 mM Tris, pH 8.0, 300 mM NaCl, 4 mM DTT, 10%
glycerol, and 10mM reduced L-glutathione). The eluted protein
was mixed with Precision Protease (GE Healthcare) and
exhaustively dialyzed against binding buffer, without ZnCl2,
over the course of 20 h at 4 °C. The cleaved protein sample was
applied to a pre-equilibrated 5-ml glutathione-agarose gravity
flow column at a flow rate of 0.5 ml/min at 4 °C, and the
flow-through was collected and concentrated using an Ami-
con-Ultra 15 concentrator (Millipore). The Bradford assay and
SDS-PAGE analysis were used to determine the quantity and
purity of the protein samples, respectively. The SETD2 R1625C
mutant was generated by site-directed mutagenesis using the
QuikChange kit (Agilent) and expressed and purified as
described above. Note that a small amount of GST-SETD2WT
and R1625C was not treated with Precision Protease but was
extensively dialyzed against binding buffer and then used for
peptide pull-down experiments (see below).
Histone Methyltransferase Assays—Histone methyltrans-
ferase assays were performed by incubating wild type SETD2 or
the R1625C variant at a final concentration of 500 nMwith 1g
of chicken oligonucleosomes (EpiCypher) and 1 Ci of
[3H]AdoMet (PerkinElmer Life Sciences) in a buffer containing
50 mM HEPES, pH 8.0, 150 mM NaCl, 2.5 mM MgCl2, 1 M
ZnCl2, and 2.5% glycerol for 16 h at room temperature (total
reaction volume was 20 l). The reactions were quenched with
0.5% TFA and then spotted onto Whatman filter paper, air-
dried, and washed four times with200 ml of a sodium bicar-
bonate (pH 9.0) solution. Then they were air-dried again and
added to liquid scintillation vials containing 5 ml of Ultima
Gold F (PerkinElmer Life Sciences). Sampleswere counted for 1
min each using an all-purpose Beckman Coulter liquid scintil-
lation counter in 3Hmode.A reactionwithout enzymewas used
as the negative control and to determine background counts.
CD Spectroscopy—For CD experiments, proteins were
exhaustively dialyzed into a buffer containing 20 mM sodium
phosphate (pH 7.0), 150mM sodium fluoride (NaF), and 0.2mM
tris(2-carboxyethyl)phosphine at 4 °C. CD spectra were col-
lected using a 0.1-cm quartz cuvette and a Chirascan Plus
instrument (Applied Photophysics Inc.) at 20 °C over the wave-
length range 185–260 nmwith a step size of 0.5 nm.A sample of
the buffer was collected over the same wavelength scan, and
absorbance values were subtracted from the final data sets.
Each sample was scanned three times, and the final plots rep-
resent the average scan with the CD signal (in millidegrees)
converted to molar ellipticity. For thermal melt curves, the CD
absorbance at 207 nmwas collected over the temperature range
from 20 to 95 °C with 1 °C temperature ramping and a temper-
ature tolerance range set to 0.2 °C. Proteins were diluted to 0.25
mg/ml for all CD data collection (protein stock concentrations
determined by A280).
Peptide Pull-downs—A total of 50 pmol of GST-tagged wild
type SETD2 or the R1625C variant was incubated with 500
pmol of each biotinylated histone peptide for 1 h at 4 °C in
peptide binding buffer (50mMTris, pH 8.0, 300mMNaCl, 0.1%
Nonidet P-40) supplemented with 2 mM DTT and 1 M ZnCl2.
Following incubation, the protein/peptide mixture was incu-
bated with streptavidin-coated magnetic beads (Pierce), pre-
equilibratedwith peptide binding buffer, for an additional 1 h at
4 °C. The beads were washed three times with peptide binding
buffer, and bound complexes were eluted with 1
 SDS loading
buffer, resolved via SDS-PAGE, and transferred to a PVDF
membrane. The membrane was probed with anti-GST anti-
body diluted to 1:4000 in 5% BSA in PBS-T. The peptides con-
TABLE 1
Primers
Target Forward primer (5–3) Reverse primer (5–3)
tSETD2 CACCATGACACAGGGCCA GGGTGTCCTTGATGCTGTT
c-Myc exon 1 GCCGCATCCACGAAACTTT TCCTTGCTCGGGTGTTGTAAG
c-Myc exon 2 TGCCCCTCAACGTTAGCTTC GGCTGCACCGAGTCGTAGTC
c-Myc exon 3 CCTGAGCAATCACCTATGAACTTG CAAGGTTGTGAGGTTGCATTTG
CDK2 exon 1 GTCGGGAACTCGGTGGGAG AGAAGGCGGACCCTGGCTC
CDK2 exon 5 CATCTGGAGCCTGGGCTGCA TGGGGAGGAGAGGGAGGGGG
CDK2 exon 6 CCCTATTCCCTGGAGATTCTG CTCCGTCCATCTTCATCCAG
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tained the budding yeast histone H3 residues 27–45 and were
mono-, di-, or trimethylated at Lys-36. In this region, the
human and budding yeast H3 sequences differ by an Ala to Ser
substitution at residue 31 and by an Arg to Lys substitution at
residue 42.
Yeast Growth Assays—Parental yeast strains were trans-
formedwith the indicated plasmids andweregrownto saturation
in appropriate selection medium. Saturated cultures were diluted
to an A600 of 0.5 and 5-fold serially diluted and plated with or
without6-AUorplatedwithorwithoutphleomycin;pictureswere
taken 2–3 days after spotting. Similarly, strains with an integrated
cryptic initiation cassette (as shown in Fig. 4) were serially diluted
and plated on URA-HIS plates with or without galactose for 3
days to detect growth. Growth on URA acted as a control for
equivalent growth for all of the strains.
Immunofluorescence Staining for H2A.X—HKC were cul-
tured for 16–18 h followed by 2-Gy radiation (RS 2000 Biolog-
ical Research Irradiator), fixed for 15 min in 4% paraformalde-
hyde, washed with cold PBS, and permeabilized (0.25% Triton
X-100 in PBS) for 10 min. After blocking with 1% hydrogen
peroxide and then 5% BSA, cells were incubated with anti-
H2A.X (1:500) at 4 °C overnight. Cells were washed using
PBST and incubated with goat anti-rabbit IgG (1:500) Cy5 for
1 h at room temperature. After washing, cells were counter-
stained using DAPI. Fluorescence signals were visualized using
confocal microscopy (LSM 700, Zeiss), and the number of foci
per cell was analyzed using Zen (LSM 700, Zeiss). 5 images/
coverslip (total of 15 images) were collected in three indepen-
dent experiments. For the radiation colony formation assay,
cells were diluted to a single cell suspension, and 300 cells were
plated on a 10-cm plate. Plates were irradiated at 0, 37, 75, 150,
and 300 rads; allowed to grow for 10 days; and then stainedwith
crystal violet. Colonies were counted manually.
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